EMA experts recommend risk reduction measures for Servier, Amgen drug; Sinking ruble hurts pharmas in Russia;

@FiercePharma: FDA tightens reins on equine compounding companies. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI Friday: Fresenius Russian partnership tanks even as Russian tanks spotted rolling into Ukraine. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Eisai 'speechless' after another Fycompa price smack-down from Germany. More | Follow @CarlyHFierce

> EMA experts have recommended measures to reduce the risks associated with a heart drug from Servier and Amgen ($AMGN). Report

> A dropping ruble is dragging down drugmakers that lean on Russian business. Report

> Belgian pharma UCB says it'll reach its target of a 30% core profit margin one year later than expected now that it's agreed to sell its generics business to two private equity firms for $1.53 billion. More

> Merck ($MRK) has signed a Januvia patient pact with pharmacy chain Numark. More

> Sanofi ($SNY) has launched its pediatric vaccine, Shan5, in India. Report

> Sun Pharma's shares hit their all-time high after unit Taro Pharmaceutical's quarterly profit grew by 49% to a record $143 million. Report

> Caverion is providing building systems for Baxter ($BAX) in Austria. More

Medical Device News

@FierceMedDev: ICYMI: Power morcellation ban unlikely, but other FDA restrictions coming soon; includes email to FDA obtained by FMD. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: The new AstraZeneca, University of Manchester center for drug delivery becomes operational in February. More | Follow @VarunSaxena2

> Microsoft 3-D audio system helps the visually impaired navigate more easily. Story

> Device for minimally invasive treatment of enlarged prostate gains CMS reimbursement. Article

Biotech News

@FierceBiotech: Biotech upstart Sage sees early efficacy for rare brain seizure drug. More | Follow @FierceBiotech

@JohnCFierce: From FierceBiotechResearch: Genentech R&D team fixes a flawed approach to Alzheimer's. Story | Follow @JohnCFierce

> Battered ArQule shares bump up on badly needed positive data for tivantinib. Article

> Fledgling Ziarco grabs a $33M transatlantic round for PhII atopic dermatitis drug. Story

> J&J chief hints at unease in China, but plots new buyouts. Item

> Merck's hepatitis C cocktail drug fails a 4-week challenge. Report

CRO News

> India's GVK snags an early-stage CRO amid global growth. News

> Charles River deepens its ties to Huntington's R&D with new deal. Item

> FDA taps Icon to help patients better weigh in on trials. Story

> PPD dives into adaptive trials with Medidata deal. Report

> AMRI tanks on disappointing sales and a dimmer outlook. Article

Biotech IT News

> Google steps up Genomics pitch with $25-a-genome storage service. More

> Team taps Wikipedia for flu forecasting data. Story

> Open-source atlas of the human proteome goes live. Article

> FDA resumes its long search for a CIO. More

> AstraZeneca strikes $150M deal to buy data analysis business. Report

Animal Health News

> Jaguar postpones IPO amid rocky market for biotech and animal health offerings. Article

> Merck to meat industry: Zilmax is safe. Item

> FDA tightens reins on equine compounding companies. Report

> MWI shares sink despite better-than-expected earnings. Story

> Zoetis beats estimates on strength of livestock products and allergy drug for dogs. News

And Finally ... Insurer Cigna ($CI), facing discrimination allegations, has agreed to restructure HIV drug benefits. More (sub. req.)

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.